Design 1
New PTSD treatment made ‘night and day difference’ for
veteran
US Veteran’s experience with Zeriscope’s Bio Ware system proves life-changing. The treatment involved 10 sessions of prolonged exposure (“PE”) therapy. Mr. Shier, a veteran who served in Afghanistan, said he started to feel better pretty quickly. “It did in 10 weeks what other treatments couldn’t do in 10 years. I’m completely off medication now, and I’m happy. It was a completely night and day difference.”
Technology-enhanced in vivo exposures in Prolonged Exposure for PTSD: A pilot randomized controlled trial
In vivo exposures (IVEs) are a key component of exposure-based treatments, during which patients approach fear-provoking, yet safe, situations in “real life.” This pilot study assessed the use of a wearable technology (Bio Ware) during IVEs to enhance Prolonged Exposure (PE) therapy for PTSD. These findings demonstrate the feasibility and safety of leveraging Bio Ware for virtual, clinician-guided IVEs during PE therapy for PTSD and suggest that virtual, clinician-guided exposures may enhance treatment outcomes.
Reducing Stroke Risk in Kids with Sickle Cell Disease
Medical University of South Carolina stroke neurologist Robert J. Adams, M.D., knows firsthand how innovation can bring about dramatic and positive change. He was one of the STOP, Stroke Prevention Trial in Sickle Cell Anemia, investigators who found that transcranial doppler ultrasonography (TCD) could be used to assess stroke risk in children with sickle cell disease (SCD) and stroke risk could be reduced by giving the highest-risk children regular blood transfusions.
Design 2
New PTSD treatment made ‘night and day difference’ for
veteran
US Veteran’s experience with Zeriscope’s Bio Ware system proves life-changing. The treatment involved 10 sessions of prolonged exposure (“PE”) therapy. Mr. Shier, a veteran who served in Afghanistan, said he started to feel better pretty quickly. “It did in 10 weeks what other treatments couldn’t do in 10 years. I’m completely off medication now, and I’m happy. It was a completely night and day difference.”
Technology-enhanced in vivo exposures in Prolonged Exposure for PTSD: A pilot randomized controlled trial
In vivo exposures (IVEs) are a key component of exposure-based treatments, during which patients approach fear-provoking, yet safe, situations in “real life.” This pilot study assessed the use of a wearable technology (Bio Ware) during IVEs to enhance Prolonged Exposure (PE) therapy for PTSD. These findings demonstrate the feasibility and safety of leveraging Bio Ware for virtual, clinician-guided IVEs during PE therapy for PTSD and suggest that virtual, clinician-guided exposures may enhance treatment outcomes.
Reducing Stroke Risk in Kids with Sickle Cell Disease
Medical University of South Carolina stroke neurologist Robert J. Adams, M.D., knows firsthand how innovation can bring about dramatic and positive change. He was one of the STOP, Stroke Prevention Trial in Sickle Cell Anemia, investigators who found that transcranial doppler ultrasonography (TCD) could be used to assess stroke risk in children with sickle cell disease (SCD) and stroke risk could be reduced by giving the highest-risk children regular blood transfusions.
Design 3
New PTSD treatment made ‘night and day difference’ for veteran
US Veteran’s experience with Zeriscope’s Bio Ware system proves life-changing. The treatment involved 10 sessions of prolonged exposure (“PE”) therapy. Mr. Shier, a veteran who served in Afghanistan, said he started to feel better pretty quickly. “It did in 10 weeks what other treatments couldn’t do in 10 years. I’m completely off medication now, and I’m happy. It was a completely night and day difference.”
Reducing Stroke Risk in Kids with Sickle Cell Disease
Medical University of South Carolina stroke neurologist Robert J. Adams, M.D., knows firsthand how innovation can bring about dramatic and positive change. He was one of the STOP, Stroke Prevention Trial in Sickle Cell Anemia, investigators who found that transcranial doppler ultrasonography (TCD) could be used to assess stroke risk in children with sickle cell disease (SCD) and stroke risk could be reduced by giving the highest-risk children regular blood transfusions.
Reducing Stroke Risk in Kids with Sickle Cell Disease
Medical University of South Carolina stroke neurologist Robert J. Adams, M.D., knows firsthand how innovation can bring about dramatic and positive change. He was one of the STOP, Stroke Prevention Trial in Sickle Cell Anemia, investigators who found that transcranial doppler ultrasonography (TCD) could be used to assess stroke risk in children with sickle cell disease (SCD) and stroke risk could be reduced by giving the highest-risk children regular blood transfusions.